Современные возможности применения пегилированного липосомального доксорубицина (келикс) в гематологии

1. Ferrans V.J. Overview of cardiac pathology in relation to anthracycline cardiac toxicity. Canc Treat Rep 1978;62:955—61.

2. Ewer M.S., Benjamin R.S. Cardiotoxicity of chemotherapeutic Drugs. In: The Chemotherapy source book. Ed. M.C. Perry. 1997. p. 649—63.

3. Olson R.D., Mushlin P.S., Breuner D.E. et al. Doxorubicin cardiotoxicity may be due to its metabolite, doxorubicinol. Proc Natl acad Sci USA 1988;85:3585—9.

4. Slamon D.J., Leyland-Jones B., Shak S. et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 2001;344:783—92.

5. Singal P.K., Iliskovic N. Doxorubicin-Induced Cardiomyopathy. N Engl J Med 1998;339:900—5.

6. Lasic D.D., Papahadjopoulos D. Liposomes revisited. Science 1995;267:1275—6.

7. Harrington K.L., Lewanski C.R., Stewart S.W. Liposomes as vehicles for targeted therapy of cancer/Part.2: Clinical development. Clin Oncol 2000;12:16—24.

8. Allen T.M., Martin F.J. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004;31(Suppl 13):5—15.

9. O'Brien M.E.R., Wigler N., Inbar M. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;5(3):440—9.

10. Gabizon A., Catane R., Uziely B. Prolonged circulation time and enhansed accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Canser Res 1994;54:987—92.

11. Theodoulou M., Hudis C. Cardiac profiles of liposomal anthracyclines. Greater cardiac safety versus conventional doxorubicin? Cancer 2004;100(10):2052—63.

12. Wingler N., O'Brien M., Rosso R. et al. Reduced cardiotoxicity and comparable efficacy in phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc ASCO 2002;21:1; s. 45a, N177.

13. Lotem M., Hubert A., Lyass O. et al. Skin toxic effects of polyethylene glycolcoated liposomal doxorubicin. Arch Dermatol 2000;136:1475—80.

14. Alberts D.S., Garcia D.J. A safety review of pegylated liposomal doxorubicin in the treatment of various malignancies. Oncology 1997; Suppl 11:54—62.

15. Szelenyi H., Siehl J., Menssen H.D. et al. Cyclophosphamide, liposomal doxorubicin and dexamethasone (CLAD) is safe and efficacious in multiple myeloma. Eur J Cancer 1999;35(Supp l4):337—44.

16. Dingeldein G.C., Hoffmann M., Huebner G. et al. Phase I/II study with liposomal-encapsulated doxorubicin in VAD-protocol for patients with multiple myeloma. Blood 2001;98:308b (abstr 4985).

17. Bartlett N., Niedzwiecki D., Johnson J. et al. A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804. Proc Am Soc Clin Oncol 2003;22:566 (abstr 2275).

18. Bastion Y., Blay J.Y., Divine M. et al. Elderly patients with aggressive non- Hodgkin's lymphoma: disease presentation, response to treatment, and survival - a groupe d' Etude des Lymphomes de l' Adulte study on 453 patients older than 69 years. J Clin Oncol 1997;15:2945—53.

19. Niitsu N., Iijima K. Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study. Ann Hematol 2001;80:602—6.

20. Ewer M.S., Martin F.J., Henderson I.C. et al. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31 (Suppl 13):161—81.

21. Martino R., Perea G., Caballero M.D. et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study. Haematologica 2002;87:822—7.

22. Topilow A.A., Mencel P.J., Nahum K. et al. Cyclophosphamide/pegylated liposomal doxorubicin/vincristine/prednisone (CDOP) in the treatment of intermediate grade non-Hodgkin's lymphoma (IGNHL): A five-year follow-up. Proc Am Soc Clin Oncol 2003;22:596 (abstr 2397).

23. Tsavaris N., Kosmas C., Vadiaka M. et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res 2002;22:1845—8.

24. Zaja F., Tomadini V., Zaccaria A. et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006;47(10):2174—80.

25. Bartlett N., Niedzwiecki D., Johnson J. et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071—9.

26. Wollina U., Graefe T., Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patient with follow-up. J Cancer Res Clin Oncol 2001;127:128—34.

27. Wollina U., Dummer R., Brockmeyer N.H. et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003;98:993—1001.

28. Pulini S., Rupoli S., Goteri G. et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica 2007;92:686—9.

29. Di Bella N.J., Khan M.M., Dakhil S.R. et al. Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: A phase II multicenter study. Clin Lymphoma 2003;3:235—40.

30. Macpherson N., Belch A., Taylor M. et al. Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: A phase II study. Leuk Lymphoma 2006;47(7):1327—32.

31. Tulpule A., Khan A.U., Mohrbacher A.F. et al. A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive Bcell non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 2004;23:602 (abstr 6688).

32. Vacca A., Ribatti D., Roncali L. et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503—8.

33. He X.S., Srkalovic G., Hsi E.D. et al. The effects of different chemotherapeutic regimens on bone marrow microvessel density in patients with multiple myeloma [abstract 2424]. Proc Am Soc Clin Oncol 2003;22:603.

34. Dimopoulos M.A., Pouli A., Zervas K. et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003;14:1039—44.

35. Hussein M.A., Rifkin R., Gregory S.A. et al. DVd versus VAd in the treatment of patients with newly diagnosed multiple myeloma (n-MM): An update from a randomized multicenter trial. Blood 2003;102:453a (abstr 1653).

36. Rifkin R.M.., Gregory S.A., Mohrbacher A., Hussein M.A. Pegylated Liposomal Doxorubicin, Vincristine, and Dexamethasone Provide Significant Reduction in Toxicity Compared with Doxorubicin, Vincristine, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. A Phase III Multicenter Randomized Trial. Cancer 2006;106:848—58.

37. Hussein M.A., Wildgust M., Fastenau J. et al. Cost effectiveness of DVd vs VAd in newly diagnosed multiple myeloma. Proc Am Soc Clin Oncol 2004;23:567 (abstr 6548).

38. Agrawal N., Hussein M.A., Elson P. et al. Pegylated doxorubicin, vincristine, reduced frequency dexamethasone and thalidomide (DVd-T) in newly diagnosed and relapsed/refractory multiple myeloma patients. Blood 2003;102:237a (abstr 831).

39. Zervas K., Dimopoulos M.A., Hatziharisi E. et al: Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD Doxil): A phase II multicenter study. Ann Oncol 2004;15:138.

40. Rossi J.-F., Jourdan E., Legouffe E. et al: Intermediate analysis of a prospective randomised comparison of standard VAD protocol (vincristine, doxorubicin and dexamethasone) and pegylated liposomal doxorubicin (Doxil/CAELYX) plus dexamethasone as a first-line treatment in multiple myeloma (MM). Blood 2003;102:447a (abstr 1631).

41. Orlowski R.Z., Voorhees P.M., Garcia R.A. et al. Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood 2003;102:449a (abstr 1639).

42. Baz R., Walker E., Karam M.A. et al. Lenalidomide and pegylated liposomal doxorubicinbased chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006;17:1766—71.

43. Orlowski R.Z.., Nagler A., Sonneveld P. et al. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. J Clin Oncol 2007;25:3892—901.

44. Hussein M.A., Anderson K.C. Role of Liposomal Anthracyclines in the Treatment of Multiple Myeloma. Semin Oncol 2004;31(Suppl 13):147—60.

45. Lopes de Menezes D.E., Pilarski L.M., Belch A.R., Alien T.M. Selective targeting of immunoliposomal doxorobicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 2000;1466(1—2):205—20.

46. Lundberg B.B., Griffiths G., Hansen H.J. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin. Int J Pharm 2000;205(1—2):101—8.